ORAL ABSTRACT: ABCL-1492 Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO Trial
Jason R. Westin(The University of Texas MD Anderson Cancer Center), Martin Janousek(Roche (Switzerland)), Astrid Pavlovsky(Fundación para la Investigación, Docencia y Prevención del Cáncer), Hideki Goto(Hokkaido University Hospital), Danielle Leão Cordeiro de Farias(Beneficência Portuguesa de São Paulo), Lalita Norasetthada(Chiang Mai University), Young‐Woo Jeon(The Catholic University of Korea Yeouido St. Mary's Hospital), Bei Hu(Levine Cancer Institute), Dai Maruyama(National Cancer Center), Connie Lee Batlevi(Memorial Sloan Kettering Cancer Center), Adam J. Olszewski(Memorial Hospital of Rhode Island), Huangming Hong(Sun Yat-sen University), Michael C. Wei(The Royal Melbourne Hospital), Muhıt Özcan(Ankara University), Shen Yin, Laura Maria Fogliatto(Hospital de Clínicas de Porto Alegre), Won-Seog Kim(Samsung Medical Center), Huilai Zhang(Tianjin Medical University Cancer Institute and Hospital), Nikesh Shah(Tampa General Hospital), Jue Wang
Cited by 0
Related Papers
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c
|Genes & Development|2000|1.3k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593